Hikal Limited (NSE: HIKAL.NS) Stock Competitors & Peer Comparison
See HIKAL.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HIKAL.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HIKAL.NS | ₹211.99 | -1.68% | 26.1B | 15.17 | ₹13.97 | +0.46% |
| JBCHEPHARM.BO | ₹2,412.25 | -3.70% | 387.3B | 50.89 | ₹47.40 | +0.91% |
| WOCKPHARMA.NS | ₹1,901.00 | +0.78% | 308.9B | 145.00 | ₹13.11 | N/A |
| WOCKPHARMA.BO | ₹1,899.85 | +0.75% | 308.5B | 144.92 | ₹13.11 | N/A |
| MEDPLUS.NS | ₹676.60 | -1.88% | 81.3B | 36.61 | ₹18.48 | N/A |
| MEDPLUS.BO | ₹676.10 | -1.89% | 81.2B | 35.96 | ₹18.80 | N/A |
| SANOFI.BO | ₹3,275.70 | -2.56% | 75.5B | 21.58 | ₹151.80 | +3.67% |
| SANOFI.NS | ₹3,274.60 | -2.33% | 75.1B | 21.49 | ₹151.80 | +3.67% |
| SUPRIYA.NS | ₹797.15 | -1.03% | 64.2B | 30.66 | ₹26.00 | +0.12% |
| SUPRIYA.BO | ₹797.00 | -0.85% | 64.1B | 32.31 | ₹24.67 | +0.12% |
Stock Comparison
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
HIKAL.NS vs JBCHEPHARM.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, HIKAL.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check JBCHEPHARM.BO's competition here
Wockhardt Limited (NSE: WOCKPHARMA.NS)
HIKAL.NS vs WOCKPHARMA.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, WOCKPHARMA.NS has a market cap of 308.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while WOCKPHARMA.NS trades at ₹1,901.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas WOCKPHARMA.NS's P/E ratio is 145.00. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to WOCKPHARMA.NS's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to WOCKPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check WOCKPHARMA.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
HIKAL.NS vs WOCKPHARMA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, WOCKPHARMA.BO has a market cap of 308.5B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while WOCKPHARMA.BO trades at ₹1,899.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas WOCKPHARMA.BO's P/E ratio is 144.92. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to WOCKPHARMA.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check WOCKPHARMA.BO's competition here
MedPlus Health Services Limited (NSE: MEDPLUS.NS)
HIKAL.NS vs MEDPLUS.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MEDPLUS.NS has a market cap of 81.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MEDPLUS.NS trades at ₹676.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MEDPLUS.NS's P/E ratio is 36.61. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, HIKAL.NS is more volatile compared to MEDPLUS.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check MEDPLUS.NS's competition here
MedPlus Health Services Limited (BSE: MEDPLUS.BO)
HIKAL.NS vs MEDPLUS.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MEDPLUS.BO has a market cap of 81.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MEDPLUS.BO trades at ₹676.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MEDPLUS.BO's P/E ratio is 35.96. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, HIKAL.NS is more volatile compared to MEDPLUS.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check MEDPLUS.BO's competition here
Sanofi India Limited (BSE: SANOFI.BO)
HIKAL.NS vs SANOFI.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SANOFI.BO has a market cap of 75.5B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SANOFI.BO trades at ₹3,275.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SANOFI.BO's P/E ratio is 21.58. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SANOFI.BO's ROE of +0.40%. Regarding short-term risk, HIKAL.NS is more volatile compared to SANOFI.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SANOFI.BO's competition here
Sanofi India Limited (NSE: SANOFI.NS)
HIKAL.NS vs SANOFI.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SANOFI.NS has a market cap of 75.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SANOFI.NS trades at ₹3,274.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SANOFI.NS's P/E ratio is 21.49. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SANOFI.NS's ROE of +0.40%. Regarding short-term risk, HIKAL.NS is more volatile compared to SANOFI.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SANOFI.NS's competition here
Supriya Lifescience Limited (NSE: SUPRIYA.NS)
HIKAL.NS vs SUPRIYA.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SUPRIYA.NS has a market cap of 64.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SUPRIYA.NS trades at ₹797.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SUPRIYA.NS's P/E ratio is 30.66. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SUPRIYA.NS's ROE of +0.18%. Regarding short-term risk, HIKAL.NS is more volatile compared to SUPRIYA.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SUPRIYA.NS's competition here
Supriya Lifescience Ltd (BSE: SUPRIYA.BO)
HIKAL.NS vs SUPRIYA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SUPRIYA.BO has a market cap of 64.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SUPRIYA.BO trades at ₹797.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SUPRIYA.BO's P/E ratio is 32.31. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SUPRIYA.BO's ROE of +0.18%. Regarding short-term risk, HIKAL.NS is more volatile compared to SUPRIYA.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SUPRIYA.BO's competition here
Kwality Pharmaceuticals Limited (BSE: KPL.BO)
HIKAL.NS vs KPL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, KPL.BO has a market cap of 35.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while KPL.BO trades at ₹3,460.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas KPL.BO's P/E ratio is 86.46. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to KPL.BO's ROE of +0.28%. Regarding short-term risk, HIKAL.NS is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check KPL.BO's competition here
Hikal Limited (BSE: HIKAL.BO)
HIKAL.NS vs HIKAL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, HIKAL.BO has a market cap of 26.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while HIKAL.BO trades at ₹212.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas HIKAL.BO's P/E ratio is 184.65. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, HIKAL.NS is more volatile compared to HIKAL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check HIKAL.BO's competition here
Fredun Pharmaceuticals Limited (BSE: FREDUN.BO)
HIKAL.NS vs FREDUN.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, FREDUN.BO has a market cap of 23.6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while FREDUN.BO trades at ₹1,429.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas FREDUN.BO's P/E ratio is 56.24. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, HIKAL.NS is more volatile compared to FREDUN.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check FREDUN.BO's competition here
Shukra Pharmaceuticals Limited (BSE: SHUKRAPHAR.BO)
HIKAL.NS vs SHUKRAPHAR.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SHUKRAPHAR.BO has a market cap of 19.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SHUKRAPHAR.BO trades at ₹44.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SHUKRAPHAR.BO's P/E ratio is 88.26. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SHUKRAPHAR.BO's ROE of +0.48%. Regarding short-term risk, HIKAL.NS is more volatile compared to SHUKRAPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SHUKRAPHAR.BO's competition here
Accent Microcell Limited (NSE: ACCENTMIC.NS)
HIKAL.NS vs ACCENTMIC.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ACCENTMIC.NS has a market cap of 14.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ACCENTMIC.NS trades at ₹590.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ACCENTMIC.NS's P/E ratio is 31.64. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ACCENTMIC.NS's competition here
Remus Pharmaceuticals Ltd. (NSE: REMUS.NS)
HIKAL.NS vs REMUS.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, REMUS.NS has a market cap of 10.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while REMUS.NS trades at ₹927.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas REMUS.NS's P/E ratio is 25.91. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is less volatile compared to REMUS.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check REMUS.NS's competition here
One Global Service Provider Ltd. (BSE: ONEGLOBAL.BO)
HIKAL.NS vs ONEGLOBAL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ONEGLOBAL.BO has a market cap of 10.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ONEGLOBAL.BO trades at ₹557.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ONEGLOBAL.BO's P/E ratio is 15.68. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ONEGLOBAL.BO's ROE of +0.71%. Regarding short-term risk, HIKAL.NS is more volatile compared to ONEGLOBAL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check ONEGLOBAL.BO's competition here
Bharat Parenterals Limited (BSE: BPLPHARMA.BO)
HIKAL.NS vs BPLPHARMA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BPLPHARMA.BO has a market cap of 10.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BPLPHARMA.BO trades at ₹1,468.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BPLPHARMA.BO's P/E ratio is -126.06. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, HIKAL.NS is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check BPLPHARMA.BO's competition here
Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO)
HIKAL.NS vs SUDARSHAN.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SUDARSHAN.BO has a market cap of 9.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SUDARSHAN.BO trades at ₹39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SUDARSHAN.BO's P/E ratio is 41.03. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SUDARSHAN.BO's ROE of +0.18%. Regarding short-term risk, HIKAL.NS is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SUDARSHAN.BO's competition here
Vikram Thermo (India) Limited (BSE: VIKRAMTH.BO)
HIKAL.NS vs VIKRAMTH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VIKRAMTH.BO has a market cap of 9.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VIKRAMTH.BO trades at ₹298.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VIKRAMTH.BO's P/E ratio is 37.44. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VIKRAMTH.BO's ROE of +0.32%. Regarding short-term risk, HIKAL.NS is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check VIKRAMTH.BO's competition here
Sastasundar Ventures Limited (NSE: SASTASUNDR.NS)
HIKAL.NS vs SASTASUNDR.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SASTASUNDR.NS trades at ₹282.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SASTASUNDR.NS's ROE of +0.00%. Regarding short-term risk, HIKAL.NS is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SASTASUNDR.NS's competition here
Praveg Ltd. (BSE: PRAVEG.BO)
HIKAL.NS vs PRAVEG.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PRAVEG.BO has a market cap of 6.8B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PRAVEG.BO trades at ₹261.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PRAVEG.BO's P/E ratio is 36.83. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, HIKAL.NS is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check PRAVEG.BO's competition here
Shree Ganesh Remedies Limited (BSE: SGRL.BO)
HIKAL.NS vs SGRL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SGRL.BO has a market cap of 6.7B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SGRL.BO trades at ₹518.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SGRL.BO's P/E ratio is 40.09. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, HIKAL.NS is more volatile compared to SGRL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SGRL.BO's competition here
Albert David Limited (BSE: ALBERTDA.BO)
HIKAL.NS vs ALBERTDA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ALBERTDA.BO's ROE of -0.01%. Regarding short-term risk, HIKAL.NS is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ALBERTDA.BO's competition here
Bafna Pharmaceuticals Ltd. (BSE: BAFNAPH.BO)
HIKAL.NS vs BAFNAPH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BAFNAPH.BO has a market cap of 6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BAFNAPH.BO trades at ₹259.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BAFNAPH.BO's P/E ratio is 55.30. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BAFNAPH.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to BAFNAPH.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check BAFNAPH.BO's competition here
Bafna Pharmaceuticals Limited (NSE: BAFNAPH.NS)
HIKAL.NS vs BAFNAPH.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BAFNAPH.NS has a market cap of 6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BAFNAPH.NS trades at ₹254.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BAFNAPH.NS's P/E ratio is 54.28. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BAFNAPH.NS's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check BAFNAPH.NS's competition here
Jenburkt Pharmaceuticals Limited (BSE: JENBURPH.BO)
HIKAL.NS vs JENBURPH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, JENBURPH.BO has a market cap of 4.6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while JENBURPH.BO trades at ₹1,038.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas JENBURPH.BO's P/E ratio is 20.14. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to JENBURPH.BO's ROE of +0.18%. Regarding short-term risk, HIKAL.NS is more volatile compared to JENBURPH.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check JENBURPH.BO's competition here
Transchem Limited (BSE: TRANSCHEM.BO)
HIKAL.NS vs TRANSCHEM.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TRANSCHEM.BO has a market cap of 4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TRANSCHEM.BO trades at ₹323.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TRANSCHEM.BO's P/E ratio is 85.92. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, HIKAL.NS is more volatile compared to TRANSCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check TRANSCHEM.BO's competition here
Infinium Pharmachem Ltd. (NSE: INFINIUM.NS)
HIKAL.NS vs INFINIUM.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, INFINIUM.NS has a market cap of 3.5B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while INFINIUM.NS trades at ₹222.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas INFINIUM.NS's P/E ratio is 36.83. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to INFINIUM.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check INFINIUM.NS's competition here
Ambalal Sarabhai Enterprises Limited (BSE: AMBALALSA.BO)
HIKAL.NS vs AMBALALSA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, AMBALALSA.BO has a market cap of 3.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while AMBALALSA.BO trades at ₹44.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas AMBALALSA.BO's P/E ratio is 19.00. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check AMBALALSA.BO's competition here
Trident Lifeline Limited (BSE: TLL.BO)
HIKAL.NS vs TLL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TLL.BO has a market cap of 3.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TLL.BO trades at ₹272.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TLL.BO's P/E ratio is 16.69. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, HIKAL.NS is more volatile compared to TLL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check TLL.BO's competition here
BDH Industries Limited (BSE: BDH.BO)
HIKAL.NS vs BDH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BDH.BO has a market cap of 2.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BDH.BO trades at ₹510.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BDH.BO's P/E ratio is 34.69. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, HIKAL.NS is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check BDH.BO's competition here
Gennex Laboratories Limited (BSE: GENNEX.BO)
HIKAL.NS vs GENNEX.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, GENNEX.BO has a market cap of 2.9B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while GENNEX.BO trades at ₹12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas GENNEX.BO's P/E ratio is 14.86. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check GENNEX.BO's competition here
Zenotech Laboratories Limited (BSE: ZENOTECH.BO)
HIKAL.NS vs ZENOTECH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ZENOTECH.BO trades at ₹45.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ZENOTECH.BO's P/E ratio is 146.77. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, HIKAL.NS is more volatile compared to ZENOTECH.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check ZENOTECH.BO's competition here
Kerala Ayurveda Limited (BSE: KERALAYUR.BO)
HIKAL.NS vs KERALAYUR.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, KERALAYUR.BO has a market cap of 2.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while KERALAYUR.BO trades at ₹186.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas KERALAYUR.BO's P/E ratio is -20.39. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to KERALAYUR.BO's ROE of -2.76%. Regarding short-term risk, HIKAL.NS is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check KERALAYUR.BO's competition here
Coral Laboratories Limited (BSE: CORALAB.BO)
HIKAL.NS vs CORALAB.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, CORALAB.BO has a market cap of 2.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while CORALAB.BO trades at ₹654.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas CORALAB.BO's P/E ratio is 17.28. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to CORALAB.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check CORALAB.BO's competition here
Sanjivani Paranteral Limited. (BSE: SANJIVIN.BO)
HIKAL.NS vs SANJIVIN.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SANJIVIN.BO has a market cap of 2.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SANJIVIN.BO trades at ₹188.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SANJIVIN.BO's P/E ratio is 50.21. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SANJIVIN.BO's ROE of +0.17%. Regarding short-term risk, HIKAL.NS is more volatile compared to SANJIVIN.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SANJIVIN.BO's competition here
Oxygenta Pharmaceutical Ltd. (BSE: OXYGENTAPH.BO)
HIKAL.NS vs OXYGENTAPH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, OXYGENTAPH.BO has a market cap of 2.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while OXYGENTAPH.BO trades at ₹60.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas OXYGENTAPH.BO's P/E ratio is -60.53. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to OXYGENTAPH.BO's ROE of +0.39%. Regarding short-term risk, HIKAL.NS is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check OXYGENTAPH.BO's competition here
Syschem (India) Limited (BSE: SYSCHEM.BO)
HIKAL.NS vs SYSCHEM.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SYSCHEM.BO has a market cap of 1.6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SYSCHEM.BO trades at ₹32.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SYSCHEM.BO's P/E ratio is 533.67. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, HIKAL.NS is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SYSCHEM.BO's competition here
Panchsheel Organics Limited (BSE: PANCHSHEEL.BO)
HIKAL.NS vs PANCHSHEEL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PANCHSHEEL.BO has a market cap of 1.6B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PANCHSHEEL.BO trades at ₹118.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PANCHSHEEL.BO's P/E ratio is 14.39. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, HIKAL.NS is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check PANCHSHEEL.BO's competition here
Auro Laboratories Limited (BSE: AUROLAB.BO)
HIKAL.NS vs AUROLAB.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, AUROLAB.BO has a market cap of 1.5B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while AUROLAB.BO trades at ₹233.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas AUROLAB.BO's P/E ratio is 38.78. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to AUROLAB.BO's ROE of +0.08%. Regarding short-term risk, HIKAL.NS is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check AUROLAB.BO's competition here
Smruthi Organics Limited (BSE: SMRUTHIORG.BO)
HIKAL.NS vs SMRUTHIORG.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SMRUTHIORG.BO has a market cap of 1.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SMRUTHIORG.BO trades at ₹126.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SMRUTHIORG.BO's P/E ratio is 19.57. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, HIKAL.NS is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SMRUTHIORG.BO's competition here
Quest Laboratories Ltd. (NSE: QUESTLAB.NS)
HIKAL.NS vs QUESTLAB.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, QUESTLAB.NS has a market cap of 1.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while QUESTLAB.NS trades at ₹86.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas QUESTLAB.NS's P/E ratio is 10.45. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is less volatile compared to QUESTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check QUESTLAB.NS's competition here
Parnax Lab Limited (BSE: PARNAXLAB.BO)
HIKAL.NS vs PARNAXLAB.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PARNAXLAB.BO has a market cap of 1.4B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PARNAXLAB.BO trades at ₹121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PARNAXLAB.BO's P/E ratio is 64.02. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, HIKAL.NS is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check PARNAXLAB.BO's competition here
Kimia Biosciences Ltd. (BSE: KIMIABL.BO)
HIKAL.NS vs KIMIABL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, KIMIABL.BO has a market cap of 1.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while KIMIABL.BO trades at ₹27.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas KIMIABL.BO's P/E ratio is 31.43. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to KIMIABL.BO's ROE of +0.55%. Regarding short-term risk, HIKAL.NS is more volatile compared to KIMIABL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check KIMIABL.BO's competition here
Makers Laboratories Limited (BSE: MAKERSL.BO)
HIKAL.NS vs MAKERSL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MAKERSL.BO has a market cap of 1.3B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MAKERSL.BO trades at ₹221.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MAKERSL.BO's P/E ratio is -175.37. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, HIKAL.NS is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check MAKERSL.BO's competition here
Lactose (India) Limited (BSE: LACTOSE.BO)
HIKAL.NS vs LACTOSE.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while LACTOSE.BO trades at ₹98.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas LACTOSE.BO's P/E ratio is 20.57. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, HIKAL.NS is more volatile compared to LACTOSE.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check LACTOSE.BO's competition here
Tyche Industries Limited (BSE: TYCHE.BO)
HIKAL.NS vs TYCHE.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TYCHE.BO trades at ₹109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TYCHE.BO's P/E ratio is 11.05. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, HIKAL.NS is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check TYCHE.BO's competition here
Pharmaids Pharmaceuticals Limited (BSE: PHARMAID.BO)
HIKAL.NS vs PHARMAID.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PHARMAID.BO trades at ₹30.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PHARMAID.BO's P/E ratio is -40.45. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, HIKAL.NS is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check PHARMAID.BO's competition here
Denis Chem Lab Limited (BSE: DENISCHEM.BO)
HIKAL.NS vs DENISCHEM.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, DENISCHEM.BO has a market cap of 1B. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while DENISCHEM.BO trades at ₹72.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas DENISCHEM.BO's P/E ratio is 11.91. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, HIKAL.NS is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check DENISCHEM.BO's competition here
Sotac Pharmaceuticals Ltd. (NSE: SOTAC.NS)
HIKAL.NS vs SOTAC.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SOTAC.NS trades at ₹90.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SOTAC.NS's P/E ratio is 11.63. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SOTAC.NS's competition here
Godavari Drugs Limited (BSE: GODAVARI.BO)
HIKAL.NS vs GODAVARI.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, GODAVARI.BO has a market cap of 982.4M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while GODAVARI.BO trades at ₹97.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas GODAVARI.BO's P/E ratio is 22.30. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, HIKAL.NS is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check GODAVARI.BO's competition here
Mercury Laboratories Limited (BSE: MERCURYLAB.BO)
HIKAL.NS vs MERCURYLAB.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MERCURYLAB.BO has a market cap of 937.2M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MERCURYLAB.BO trades at ₹781.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MERCURYLAB.BO's P/E ratio is 25.65. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, HIKAL.NS is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check MERCURYLAB.BO's competition here
Vaishali Pharma Limited (NSE: VAISHALI.NS)
HIKAL.NS vs VAISHALI.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VAISHALI.NS has a market cap of 870.4M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VAISHALI.NS trades at ₹8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VAISHALI.NS's P/E ratio is -3.01. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, HIKAL.NS is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check VAISHALI.NS's competition here
Concord Drugs Limited (BSE: CONCORD.BO)
HIKAL.NS vs CONCORD.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, CONCORD.BO has a market cap of 851.3M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while CONCORD.BO trades at ₹76.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas CONCORD.BO's P/E ratio is 80.69. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to CONCORD.BO's ROE of +0.03%. Regarding short-term risk, HIKAL.NS is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check CONCORD.BO's competition here
Sunil Healthcare Ltd. (BSE: SUNLOC.BO)
HIKAL.NS vs SUNLOC.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SUNLOC.BO has a market cap of 742.1M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SUNLOC.BO trades at ₹72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SUNLOC.BO's P/E ratio is 18.51. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, HIKAL.NS is less volatile compared to SUNLOC.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SUNLOC.BO's competition here
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS)
HIKAL.NS vs ZENITHDRUG.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ZENITHDRUG.NS has a market cap of 706.5M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ZENITHDRUG.NS trades at ₹41.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ZENITHDRUG.NS's P/E ratio is 17.91. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to ZENITHDRUG.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check ZENITHDRUG.NS's competition here
Bharat Immunologicals & Biologicals Corporation Limited (BSE: BIBCL.BO)
HIKAL.NS vs BIBCL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BIBCL.BO has a market cap of 682.2M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BIBCL.BO trades at ₹15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BIBCL.BO's P/E ratio is -4.46. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, HIKAL.NS is more volatile compared to BIBCL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check BIBCL.BO's competition here
Source Natural Foods & Herbal Supplements Ltd. (BSE: SOURCENTRL.BO)
HIKAL.NS vs SOURCENTRL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SOURCENTRL.BO has a market cap of 679.4M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SOURCENTRL.BO trades at ₹105.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SOURCENTRL.BO's P/E ratio is 19.99. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, HIKAL.NS is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SOURCENTRL.BO's competition here
Vilin Bio Med Ltd. (NSE: VILINBIO.NS)
HIKAL.NS vs VILINBIO.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VILINBIO.NS has a market cap of 601.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VILINBIO.NS trades at ₹43.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VILINBIO.NS's P/E ratio is 269.69. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to VILINBIO.NS. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check VILINBIO.NS's competition here
Phaarmasia Limited (BSE: PHRMASI.BO)
HIKAL.NS vs PHRMASI.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PHRMASI.BO has a market cap of 518.8M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PHRMASI.BO trades at ₹76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PHRMASI.BO's P/E ratio is -26.42. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PHRMASI.BO's ROE of +1.35%. Regarding short-term risk, HIKAL.NS is more volatile compared to PHRMASI.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check PHRMASI.BO's competition here
Parmax Pharma Limited (BSE: PARMAX.BO)
HIKAL.NS vs PARMAX.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PARMAX.BO has a market cap of 490.7M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PARMAX.BO trades at ₹131.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PARMAX.BO's P/E ratio is -11.79. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PARMAX.BO's ROE of +0.96%. Regarding short-term risk, HIKAL.NS is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check PARMAX.BO's competition here
Vasundhara Rasayans Limited (BSE: VRL.BO)
HIKAL.NS vs VRL.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VRL.BO has a market cap of 487.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VRL.BO trades at ₹153.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VRL.BO's P/E ratio is 8.42. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, HIKAL.NS is more volatile compared to VRL.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check VRL.BO's competition here
Vista Pharmaceuticals Limited (BSE: VISTAPH.BO)
HIKAL.NS vs VISTAPH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VISTAPH.BO has a market cap of 405.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VISTAPH.BO trades at ₹6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VISTAPH.BO's P/E ratio is -3.41. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, HIKAL.NS is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check VISTAPH.BO's competition here
Roopa Industries Limited (BSE: ROOPAIND.BO)
HIKAL.NS vs ROOPAIND.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ROOPAIND.BO has a market cap of 400M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ROOPAIND.BO trades at ₹50.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ROOPAIND.BO's P/E ratio is 391.23. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, HIKAL.NS is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ROOPAIND.BO's competition here
Shelter Pharma Limited (BSE: SHELTER.BO)
HIKAL.NS vs SHELTER.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SHELTER.BO has a market cap of 390.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SHELTER.BO trades at ₹33.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SHELTER.BO's P/E ratio is 6.54. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SHELTER.BO's ROE of +0.15%. Regarding short-term risk, HIKAL.NS is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SHELTER.BO's competition here
Sandu Pharmaceuticals Limited (BSE: SANDUPHQ.BO)
HIKAL.NS vs SANDUPHQ.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SANDUPHQ.BO has a market cap of 366.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SANDUPHQ.BO trades at ₹37.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SANDUPHQ.BO's P/E ratio is 149.65. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, HIKAL.NS is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SANDUPHQ.BO's competition here
Panjon Ltd. (BSE: PANJON.BO)
HIKAL.NS vs PANJON.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PANJON.BO has a market cap of 337.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PANJON.BO trades at ₹19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PANJON.BO's P/E ratio is 491.75. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, HIKAL.NS is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check PANJON.BO's competition here
Medi-Caps Limited (BSE: MEDICAPQ.BO)
HIKAL.NS vs MEDICAPQ.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MEDICAPQ.BO has a market cap of 336.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MEDICAPQ.BO trades at ₹26.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MEDICAPQ.BO's P/E ratio is 40.28. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, HIKAL.NS is less volatile compared to MEDICAPQ.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check MEDICAPQ.BO's competition here
ANG Lifesciences India Limited (BSE: ANG.BO)
HIKAL.NS vs ANG.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ANG.BO has a market cap of 333.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ANG.BO trades at ₹25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ANG.BO's P/E ratio is -3.00. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ANG.BO's ROE of -0.22%. Regarding short-term risk, HIKAL.NS is less volatile compared to ANG.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ANG.BO's competition here
Deccan Health Care Ltd (BSE: DECCAN.BO)
HIKAL.NS vs DECCAN.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, DECCAN.BO has a market cap of 326.2M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while DECCAN.BO trades at ₹13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas DECCAN.BO's P/E ratio is 12.92. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, HIKAL.NS is more volatile compared to DECCAN.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check DECCAN.BO's competition here
Gujarat Terce Laboratories Limited (BSE: GUJTERC.BO)
HIKAL.NS vs GUJTERC.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, GUJTERC.BO has a market cap of 292.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while GUJTERC.BO trades at ₹37.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas GUJTERC.BO's P/E ratio is 41.40. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to GUJTERC.BO's ROE of +0.26%. Regarding short-term risk, HIKAL.NS is more volatile compared to GUJTERC.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check GUJTERC.BO's competition here
Medicamen Organics Ltd (NSE: MEDIORG.NS)
HIKAL.NS vs MEDIORG.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, MEDIORG.NS has a market cap of 281.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while MEDIORG.NS trades at ₹23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas MEDIORG.NS's P/E ratio is -6.79. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is less volatile compared to MEDIORG.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check MEDIORG.NS's competition here
Welcure Drugs & Pharmaceuticals Limited (BSE: WELCURE.BO)
HIKAL.NS vs WELCURE.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, WELCURE.BO has a market cap of 271.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while WELCURE.BO trades at ₹0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas WELCURE.BO's P/E ratio is -10.93. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, HIKAL.NS is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check WELCURE.BO's competition here
Trimurthi Limited (BSE: TRIMURTHI.BO)
HIKAL.NS vs TRIMURTHI.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TRIMURTHI.BO's ROE of +0.02%. Regarding short-term risk, HIKAL.NS is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check TRIMURTHI.BO's competition here
Ishita Drugs and Industries Limited (BSE: ISHITADR.BO)
HIKAL.NS vs ISHITADR.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ISHITADR.BO has a market cap of 221.3M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ISHITADR.BO trades at ₹74.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ISHITADR.BO's P/E ratio is 185.65. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, HIKAL.NS is less volatile compared to ISHITADR.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ISHITADR.BO's competition here
Chemo Pharma Laboratories Limited (BSE: CHEMOPH.BO)
HIKAL.NS vs CHEMOPH.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to CHEMOPH.BO's ROE of -0.92%. Regarding short-term risk, HIKAL.NS is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check CHEMOPH.BO's competition here
Colinz Laboratories Limited (BSE: COLINZ.BO)
HIKAL.NS vs COLINZ.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, COLINZ.BO has a market cap of 179M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while COLINZ.BO trades at ₹71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas COLINZ.BO's P/E ratio is 169.17. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, HIKAL.NS is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check COLINZ.BO's competition here
Sunrest Lifescience Ltd. (NSE: SUNREST.NS)
HIKAL.NS vs SUNREST.NS Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SUNREST.NS has a market cap of 175.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SUNREST.NS trades at ₹41.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SUNREST.NS's P/E ratio is 8.78. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, HIKAL.NS is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check SUNREST.NS's competition here
Bacil Pharma Limited (BSE: BACPHAR.BO)
HIKAL.NS vs BACPHAR.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BACPHAR.BO has a market cap of 169.1M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BACPHAR.BO trades at ₹11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BACPHAR.BO's P/E ratio is 39.45. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BACPHAR.BO's ROE of +0.03%. Regarding short-term risk, HIKAL.NS is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check BACPHAR.BO's competition here
Zenlabs Ethica Limited (BSE: ZENLABS.BO)
HIKAL.NS vs ZENLABS.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ZENLABS.BO has a market cap of 163M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ZENLABS.BO trades at ₹25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ZENLABS.BO's P/E ratio is -8.43. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ZENLABS.BO's ROE of -0.19%. Regarding short-term risk, HIKAL.NS is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check ZENLABS.BO's competition here
Norris Medicines Limited (BSE: NORRIS.BO)
HIKAL.NS vs NORRIS.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, NORRIS.BO has a market cap of 159.1M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while NORRIS.BO trades at ₹15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, HIKAL.NS is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check NORRIS.BO's competition here
Shamrock Industrial Co. Ltd. (BSE: SHAMROIN.BO)
HIKAL.NS vs SHAMROIN.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, SHAMROIN.BO has a market cap of 140.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while SHAMROIN.BO trades at ₹25.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas SHAMROIN.BO's P/E ratio is -282.42. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to SHAMROIN.BO's ROE of -0.98%. Regarding short-term risk, HIKAL.NS is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check SHAMROIN.BO's competition here
Kobo Biotech Ltd. (BSE: KOBO.BO)
HIKAL.NS vs KOBO.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, KOBO.BO has a market cap of 121.5M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while KOBO.BO trades at ₹5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas KOBO.BO's P/E ratio is -9.87. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, HIKAL.NS is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check KOBO.BO's competition here
Emmessar Biotech & Nutrition Limited (BSE: EMMESSA.BO)
HIKAL.NS vs EMMESSA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, EMMESSA.BO has a market cap of 119.5M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while EMMESSA.BO trades at ₹23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas EMMESSA.BO's P/E ratio is 79.73. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, HIKAL.NS is more volatile compared to EMMESSA.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check EMMESSA.BO's competition here
Beryl Drugs Limited (BSE: BERLDRG.BO)
HIKAL.NS vs BERLDRG.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, BERLDRG.BO has a market cap of 114.1M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while BERLDRG.BO trades at ₹22.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas BERLDRG.BO's P/E ratio is 36.64. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, HIKAL.NS is more volatile compared to BERLDRG.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check BERLDRG.BO's competition here
Trinity League India Limited (BSE: TRINITYLEA.BO)
HIKAL.NS vs TRINITYLEA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TRINITYLEA.BO has a market cap of 79.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TRINITYLEA.BO trades at ₹10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TRINITYLEA.BO's P/E ratio is -50.25. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TRINITYLEA.BO's ROE of -0.06%. Regarding short-term risk, HIKAL.NS is less volatile compared to TRINITYLEA.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check TRINITYLEA.BO's competition here
Vivanza Biosciences Limited (BSE: VIVANZA.BO)
HIKAL.NS vs VIVANZA.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, VIVANZA.BO has a market cap of 72M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while VIVANZA.BO trades at ₹1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas VIVANZA.BO's P/E ratio is -185.57. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, HIKAL.NS is more volatile compared to VIVANZA.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check VIVANZA.BO's competition here
Ganga Pharmaceuticals Limited (BSE: GANGAPHARM.BO)
HIKAL.NS vs GANGAPHARM.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, HIKAL.NS is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check GANGAPHARM.BO's competition here
Hindustan Bio Sciences Limited (BSE: HINDBIO.BO)
HIKAL.NS vs HINDBIO.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, HINDBIO.BO has a market cap of 69.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while HINDBIO.BO trades at ₹6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas HINDBIO.BO's P/E ratio is 46.27. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, HIKAL.NS is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check HINDBIO.BO's competition here
Tiaan Consumer Ltd. (BSE: TIAANC.BO)
HIKAL.NS vs TIAANC.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TIAANC.BO trades at ₹6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, HIKAL.NS is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for HIKAL.NS.Check TIAANC.BO's competition here
Adline Chem Lab Ltd. (BSE: ADLINE.BO)
HIKAL.NS vs ADLINE.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, ADLINE.BO has a market cap of 62.2M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while ADLINE.BO trades at ₹10.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check ADLINE.BO's competition here
Decipher Labs Ltd. (BSE: DECIPHER.BO)
HIKAL.NS vs DECIPHER.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, DECIPHER.BO has a market cap of 57.6M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while DECIPHER.BO trades at ₹5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas DECIPHER.BO's P/E ratio is -0.71. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, HIKAL.NS is more volatile compared to DECIPHER.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check DECIPHER.BO's competition here
Fabino Enterprises Ltd (BSE: FABINO.BO)
HIKAL.NS vs FABINO.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while FABINO.BO trades at ₹20.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, HIKAL.NS is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check FABINO.BO's competition here
TMT (India) Ltd. (BSE: TMTIND-B1.BO)
HIKAL.NS vs TMTIND-B1.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, TMTIND-B1.BO has a market cap of 41.9M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while TMTIND-B1.BO trades at ₹8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas TMTIND-B1.BO's P/E ratio is -46.94. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, HIKAL.NS is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check TMTIND-B1.BO's competition here
Patidar Buildcon Limited (BSE: PATIDAR.BO)
HIKAL.NS vs PATIDAR.BO Comparison August 2026
Hikal Limited (NSE: HIKAL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HIKAL.NS stands at 26.1B. In comparison, PATIDAR.BO has a market cap of 27.5M. Regarding current trading prices, HIKAL.NS is priced at ₹211.99 on the NSE, while PATIDAR.BO trades at ₹5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HIKAL.NS currently has a P/E ratio of 15.17, whereas PATIDAR.BO's P/E ratio is -11.63. In terms of profitability, HIKAL.NS's ROE is -0.03%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, HIKAL.NS is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for HIKAL.NS.Check PATIDAR.BO's competition here